Drug Type AAV based gene therapy |
Synonyms Recombinant AAV9 viral vector containing the transgene encoding the human WW domain-containing oxidoreductase (WWOX) protein, under the control of a human Synapsin I promoter |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epileptic encephalopathy | Preclinical | US | ![]() | 07 Dec 2023 |